TScan Therapeutics

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Study start-up activities now ongoing for all three arms of the Phase 1 umbrella trial of TSC-100 and TSC-101 Study start-up activities now ongoing for all three arms of the Phase 1 umbrella trial of TSC-100 and TSC-101

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies

Identified lead TCR-T cell therapy candidate, TCR-200-A02, for the treatment of HPV-positive solid tumors, on track for IND submission in 2H22

TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the H.C. Wainwright Global Investment Conference that will be available for viewing on Tuesday, May 24, 2022, at 7:00 a.m. ET.

TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will host a virtual key opinion leader (KOL) event, to discuss highlights from its presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting as well as its solid tumor program on Thursday, May 19, 2022, at 4:30 p.m. ET.

TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting

Preclinical data to be presented at the American Society of Gene & Cell Therapy 25 th Annual Meeting; virtual KOL event following the conference

TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones

Company to host a virtual KOL event to discuss highlights from the meeting on Thursday, May 19, 2022, at 4:30 p.m. ET Company to host a virtual KOL event to discuss highlights from the meeting on Thursday, May 19, 2022, at 4:30 p.m. ET

TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting

WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Leiden Dworak, CPA, MBA, as Vice President, Finance. Mr. Dworak brings to TScan over a decade of experience in financial infrastructure implementation and operations management in early/mid-stage biotech.

TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance

Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies

TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities

WALTHAM, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 12:00 p.m. Eastern Time.

TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare Conference

The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies patients undergoing allogeneic hematopoietic cell transplantation (HCT).  The target of TSC-100 is the minor histocompatibility antigen HA-1, which is a lineage-specific antigen found on blood cells.

FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies

– Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 –

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies

IND Submissions Completed in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Candidates TSC-100 and TSC-101

TScan Outlines 2022 Priorities as Programs Enter Clinic

-  Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 -

TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition

- Event to feature Dr. Yi-Bin Chen, M.D., M.S., from MGH and Harvard Medical School - - Event to feature Dr. Yi-Bin Chen, M.D., M.S., from MGH and Harvard Medical School -

TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition

- Completion of facility supports upcoming clinical milestones including expected multiple fourth quarter IND filings - - Completion of facility supports upcoming clinical milestones including expected multiple fourth quarter IND filings -

TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies

IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101

TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that two abstracts related to its lead liquid tumor candidates TSC-100 and TSC-101 have been accepted for poster presentations at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition, being held from December 11-14, 2021. Abstracts are available on the ASH website at www.hematology.org. TSC-100 and TSC-101 are TCR-T cell products directed against the minor histocompatibility antigens HA-1 and HA-2, respectively, which are found only on blood cells. TScan is developing these products to prevent relapse following hematopoietic cell transplant (HCT) in myeloid leukemia. The Company plans to file investigational new drug applications (INDs) for both programs before the end of 2021.

TScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition

The mean of analysts' price targets for TScan Therapeutics, Inc. (TCRX) points to a 147.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe TScan Therapeutics, Inc. (TCRX) Could Rally 147%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 214.5% in TScan Therapeutics, Inc. (TCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 215% Upside in TScan Therapeutics, Inc. (TCRX): Can the Stock Really Move This High?

WALTHAM, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Heather Savelle as Vice President, Investor Relations. Ms. Savelle brings to TScan over 20 years of experience in corporate communications and investor relations.

TScan Therapeutics Appoints Heather Savelle as Vice President, Investor Relations

WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:00 p.m. ET.

TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that Zoran Zdraveski, J.D., Ph.D. has been appointed as Chief Legal Officer.

TScan Therapeutics Appoints Zoran Zdraveski, J.D., Ph.D. as Chief Legal Officer

WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 4:15 p.m. ET.

TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs

TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T cell target discoveries Company advancing research of a next-generation vaccine construct for SARS-CoV-2 using T cell target discoveries

News for TScan Therapeutics Stock (TCRX)